51 completed, 40 recruiting, 20 terminated, 13 withdrawn. 83 Phase 1, 48 Phase 2, 18 Not applicable, 5 Early Phase 1, 5 Phase 3.
Follow Leukapheresis: new trials by email Literature Review of Leukapheresis trials Research Report on Leukapheresis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | City of Hope Medical Center | 19 | 2026-12-14 | 2026-05-13 |
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography - Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 1 | Suspended | Roswell Park Cancer Institute | 24 | 2026-11-15 | 2026-09-15 |
| Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders Filgrastim, Plerixafor, Leukapheresis - Bone Marrow Failure Syndrome | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 12 | 2026-11-01 | 2026-10-06 |
| IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | Fred Hutchinson Cancer Center | 20 | 2026-10-31 | 2026-09-04 |
| Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Recruiting | Uma Borate | 70 | 2026-10-01 | 2026-08-27 |
| GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin - Lymphoma, B-cell Lymphomas | Phase 2 | Recruiting | Massachusetts General Hospital | 56 | 2026-09-15 | 2026-10-22 |
| Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection - Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype | Phase 1 | Recruiting | City of Hope Medical Center | 24 | 2026-05-26 | 2026-10-23 |
| N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy Biospecimen Collection, Computed Tomography, Leukapheresis - Myxoid Liposarcoma, Round Cell Liposarcoma | Early Phase 1 | Recruiting | Seth Pollack | 8 | 2026-04-13 | 2026-08-27 |
| Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma Leukapheresis, Lymphodepleting Chemotherapy - Large B-cell Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2026-03-17 | 2026-06-30 |
| 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 30 | 2026-03-06 | 2026-04-20 |
| CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma Leukapheresis, Cyclophosphamide, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Suspended | Thomas Martin, MD | 30 | 2026-02-28 | 2026-06-11 |
| Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells Axicabtagene Ciloleucel, Biospecimen Collection, Chemotherapy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Phase 2 | Recruiting | City of Hope Medical Center | 56 | 2026-02-11 | 2026-03-05 |
| Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Roswell Park Cancer Institute | 26 | 2026-02-02 | 2026-10-27 |
| CAR-DC for End-Stage IPF Leukapheresis, CAR-DC - Idiopathic Pulmonary Fibrosis(IPF) | Phase 1 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 8 | 2026-02-01 | 2026-01-09 |
| Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial FH FOLR1 ST CAR T-cells, Leukapheresis, Fludarabine - Advanced Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2026-01-16 | 2026-09-01 |
| Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection - Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2025-12-30 | 2026-04-27 |
| ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Suspended | Fred Hutchinson Cancer Center | 33 | 2025-12-27 | 2026-09-11 |
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
Showing 20 of 152. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (16) · Multiple Myeloma (14) · Leukemia, Myeloid, Acute (12) · Lymphoma, Non-Hodgkin (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (10) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Lymphoma (8) · Lymphoma, B-Cell (8) · Lymphoma, Follicular (8) · Lymphoma, Mantle-Cell (8) · Burkitt Lymphoma (7) · Glioblastoma (7) · Hodgkin Disease (6) · Prostatic Neoplasms (6) · Recurrence (5)
City of Hope Medical Center (18) · Washington University School of Medicine (15) · Fred Hutchinson Cancer Center (12) · M.D. Anderson Cancer Center (8) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Jonsson Comprehensive Cancer Center (6) · Mayo Clinic (5) · Roswell Park Cancer Institute (5) · Hebei Senlang Biotechnology Inc., Ltd. (4) · Memorial Sloan Kettering Cancer Center (4) · University of Washington (4) · National Cancer Institute (NCI) (3) · University College, London (3) · Canadian Immunodeficiency Research Collaborative (2) · H. Lee Moffitt Cancer Center and Research Institute (2)
United States (122) · United Kingdom (6) · China (5) · Australia (2) · Canada (2) · France (2) · Belgium (1) · Germany (1) · Italy (1) · Japan (1) · Mexico (1) · New Zealand (1) · Puerto Rico (1) · South Korea (1) · Switzerland (1)
Ibrahim Aldoss (4) · Amanda Cashen, M.D. (3) · Baoen Shan, PhD & MD (3) · Behnam Badie (3) · Lihong Liu, PhD & MD (3) · Brad S Kahl, M.D. (2) · John DiPersio, M.D., Ph.D. (2) · Mary Disis (2) · Rosa Nadal Rios, MD, PhD (2) · Sandy Feng, MD, PhD (2) · Sergio Giralt, MD (2) · Aimee C. Talleur, MD (1) · Ajay Gopal (1) · Alex Chehrazi-Raffle, MD (1) · Alexandre V. Hirayama, MD (1)
PMID 34515338, PMID 16556705, PMID 19933869, PMID 24055823, PMID 26826432, PMID 27190628, PMID 27482888, PMID 28292947, PMID 30978434, PMID 31477906, PMID 31650176, PMID 32126141, PMID 34797911, PMID 34871371, PMID 35115306, PMID 35196021, PMID 36275715, PMID 36945773, PMID 37640679, PMID 37647647, PMID 38713894, PMID 39820359, PMID 40198877, PMID 40593578, PMID 41052404, PMID 42341322
P30CA033572 (16), P01CA018029 (2), P30CA015704 (2), P50CA171963 (2), 2015 (1), F32CA200253 (1), P30CA014089 (1), P30CA015083 (1), P30CA016056 (1), P30CA022453 (1), P30CA043703 (1), P30CA060553 (1), P50CA097186 (1), P50CA228944 (1), R01CA129517 (1)